Related Experiment Video
Updated: May 20, 2026
07:43
Intracarotid Cancer Cell Injection to Produce Mouse Models of Brain Metastasis
Published on: February 8, 2017
Elevated PLGF contributes to small-cell lung cancer brain metastasis
1Department of Developmental Biology, Key Laboratory of Cell Biology, Ministry of Public Health and Key Laboratory of Medical Cell Biology, Ministry of Education, China Medical University, Shenyang, China.
Oncogene
|July 17, 2012
Summary
High placental growth factor (PLGF) levels in small-cell lung cancer (SCLC) patients correlate with brain metastasis. Targeting PLGF may inhibit SCLC brain metastasis and serve as a therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Metastasis
Background:
- Brain metastasis (BM) is a primary cause of death in small-cell lung cancer (SCLC) patients.
- The molecular mechanisms driving SCLC BM are poorly understood due to limited research.
Purpose of the Study:
- To investigate the molecular pathways involved in SCLC brain metastasis.
- To identify potential biomarkers and therapeutic targets for SCLC BM.
Main Methods:
- Serum levels of candidate soluble factors were screened in SCLC patients.
- An in vitro blood-brain barrier model was used to study SCLC cell migration.
- An experimental BM model was employed to assess the role of PLGF.
Main Results:
- Elevated serum placental growth factor (PLGF) levels were associated with a higher incidence of BM in SCLC patients.
- PLGF from SCLC cells activates the VEGFR-1-Rho-ERK1/2 signaling pathway, disrupting brain endothelial tight junctions and promoting cell migration.
- Downregulating PLGF significantly reduced SCLC cell metastasis to the brain in vivo.
Conclusions:
- PLGF is a potential biomarker for SCLC brain metastasis.
- PLGF represents a promising therapeutic target for preventing and treating SCLC BM.
